Efficacy and Safety of Miebo® (Perfluorohexyloctane Ophthalmic Solution) in Treating Dry Eye Disease - a narrative review
DOI:
https://doi.org/10.12775/QS.2024.16.52893Keywords
Dry eye disease, perfluorohexyloctane, Miebo®, meibomian gland dysfunction, efficacy, safetyAbstract
Introduction: Dry eye disease (DED) is a prevalent and debilitating ocular condition characterized by discomfort, visual disturbances, and tear film instability. Recent therapeutic developments have introduced perfluorohexyloctane ophthalmic solution (Miebo®) as a potential treatment for DED, particularly in patients with meibomian gland dysfunction (MGD).
Aim of the Study: This narrative review aims to evaluate the efficacy and safety of Miebo® in treating DED based on current clinical evidence.
Materials and Methods: A comprehensive literature search was conducted in PubMed, Embase, and Cochrane Library databases up to May 2024 resulting in the identification of 9 studies. The review included randomized controlled trials, prospective cohort studies, and systematic reviews that focused on the use of Miebo® for DED. Data on efficacy in improving tear film stability and symptom relief, as well as safety profiles, were extracted and analyzed.
Results: The evidence indicates that Miebo® significantly enhances tear film stability and alleviates symptoms of DED, with pronounced benefits observed in patients with MGD. Comparative studies demonstrate that Miebo® is more effective than conventional treatments, such as artificial tears and lipid-based formulations. Safety assessments reveal minimal ocular surface discomfort and no significant systemic adverse events associated with Miebo® use.
Conclusion: Miebo® shows substantial efficacy and a favorable safety profile in managing DED, making it a valuable therapeutic option, particularly for patients who do not respond to traditional therapies. However, further research is needed to confirm its long-term effectiveness and safety.
References
Ballesteros-Sánchez, A., De-Hita-Cantalejo, C., Sánchez-González, M. C., Jansone-Langine, Z., de Sotomayor, M. A., Culig, J., & Sánchez-González, J. M. (2023). Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent. In Ocular Surface (Vol. 30, pp. 254–262). Elsevier Inc. https://doi.org/10.1016/j.jtos.2023.10.001
Baudouin, C., Aragona, P., Messmer, E. M., Tomlinson, A., Calonge, M., Boboridis, K. G., Akova, Y. A., Geerling, G., Labetoulle, M., & Rolando, M. (2013). Role of hyperosmolarity in the pathogenesis and management of dry eye disease: Proceedings of the ocean group meeting. In Ocular Surface (Vol. 11, Issue 4, pp. 246–258). Elsevier Inc. https://doi.org/10.1016/j.jtos.2013.07.003
Baudouin, C., Messmer, E. M., Aragona, P., Geerling, G., Akova, Y. A., Benítez-Del-Castillo, J., Boboridis, K. G., Merayo-Lloves, J., Rolando, M., & Labetoulle, M. (2016). Revisiting the vicious circle of dry eye disease: A focus on the pathophysiology of meibomian gland dysfunction. In British Journal of Ophthalmology (Vol. 100, Issue 3, pp. 300–306). BMJ Publishing Group. https://doi.org/10.1136/bjophthalmol-2015-307415
Bradley, J. L., Stillman, I. Ö., Pivneva, I., Guerin, A., Evans, A. M., & Dana, R. (2019). Dry eye disease ranking among common reasons for seeking eye care in a large US claims database. Clinical Ophthalmology, 13, 225–232. https://doi.org/10.2147/OPTH.S188314
Bron, A. J., de Paiva, C. S., Chauhan, S. K., Bonini, S., Gabison, E. E., Jain, S., Knop, E., Markoulli, M., Ogawa, Y., Perez, V., Uchino, Y., Yokoi, N., Zoukhri, D., & Sullivan, D. A. (2017). TFOS DEWS II pathophysiology report. In Ocular Surface (Vol. 15, Issue 3, pp. 438–510). Elsevier Inc. https://doi.org/10.1016/j.jtos.2017.05.011
Craig, J. P., Nichols, K. K., Akpek, E. K., Caffery, B., Dua, H. S., Joo, C. K., Liu, Z., Nelson, J. D., Nichols, J. J., Tsubota, K., & Stapleton, F. (2017). TFOS DEWS II Definition and Classification Report. In Ocular Surface (Vol. 15, Issue 3, pp. 276–283). Elsevier Inc. https://doi.org/10.1016/j.jtos.2017.05.008
Giannaccare, G., Ghelardini, C., Mancini, A., Scorcia, V., & Mannelli, L. D. C. (2022). New perspectives in the pathophysiology and treatment of pain in patients with dry eye disease. Journal of Clinical Medicine, 11(1). https://doi.org/10.3390/jcm11010108
Huh, J., Choi, S. Y., Eom, Y., Kim, H. M., & Song, J. S. (2019). Changes in the Matrix Metalloproteinase 9 Point-of-Care Test Positivity According to MMP-9 Concentration and Loading Volume. www.corneajrnl.com
Lemp, M. A., Bron, A. J., Baudouin, C., Bentez Del Castillo, J. M., Geffen, D., Tauber, J., Foulks, G. N., Pepose, J. S., & Sullivan, B. D. (2011). Tear osmolarity in the diagnosis and management of dry eye disease. American Journal of Ophthalmology, 151(5), 792-798.e1. https://doi.org/10.1016/j.ajo.2010.10.032
Lemp, M. A., Crews, L. A., Bron, A. J., Foulks, G. N., & Sullivan, B. D. (2012). Distribution of Aqueous-Deficient and Evaporative Dry Eye in a Clinic-Based Patient Cohort: A Retrospective Study. In | www.corneajrnl.com Cornea (Vol. 31, Issue 5). www.corneajrnl.com
McDonald, M., Patel, D. A., Keith, M. S., & Snedecor, S. J. (2016). Economic and Humanistic Burden of Dry Eye Disease in Europe, North America, and Asia: A Systematic Literature Review. In Ocular Surface (Vol. 14, Issue 2, pp. 144–167). Elsevier Inc. https://doi.org/10.1016/j.jtos.2015.11.002
Navarro-Lopez, S., Moya-Ramón, M., Gallar, J., Carracedo, G., & Aracil-Marco, A. (2023). Effects of physical activity/exercise on tear film characteristics and dry eye associated symptoms: A literature review. Contact Lens and Anterior Eye, 46(4). https://doi.org/10.1016/j.clae.2023.101854
Nelson, J. D., Craig, J. P., Akpek, E. K., Azar, D. T., Belmonte, C., Bron, A. J., Clayton, J. A., Dogru, M., Dua, H. S., Foulks, G. N., Gomes, J. A. P., Hammitt, K. M., Holopainen, J., Jones, L., Joo, C. K., Liu, Z., Nichols, J. J., Nichols, K. K., Novack, G. D., … Sullivan, D. A. (2017). TFOS DEWS II Introduction. In Ocular Surface (Vol. 15, Issue 3, pp. 269–275). Elsevier Inc. https://doi.org/10.1016/j.jtos.2017.05.005
Pisella, P. J., & Pouliquen, P. (2002). Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. In Br J Ophthalmol (Vol. 86). http://bjo.bmj.com/
Protzko, E. E., Segal, B. A., Korenfeld, M. S., Krösser, S., & Vittitow, J. L. (2023). Long-Term Safety and Efficacy of Perfluorohexyloctane Ophthalmic Solution for the Treatment of Patients With Dry Eye Disease: The KALAHARI Study. Cornea. https://doi.org/10.1097/ico.0000000000003418
Rabensteiner, D. F., Aminfar, H., Boldin, I., Schwantzer, G., & Horwath-Winter, J. (2018). The prevalence of meibomian gland dysfunction, tear film and ocular surface parameters in an Austrian dry eye clinic population. Acta Ophthalmologica, 96(6), e707–e711. https://doi.org/10.1111/aos.13732
Rocha-De-Lossada, C., Sánchez-González, J. M., Zamorano-Martín, F., Rachwani-Anil, R., Torras-Sanvicens, J., & Peraza-Nieves, J. (2021). Influence of Sodium Hyaluronate Concentration in Tear Meniscus Height: 10-min Dynamic Profile After Single Instillation. Eye and Contact Lens, 47(6), 330–334. https://doi.org/10.1097/ICL.0000000000000733
Sánchez-González, J. M., Rocha-de-Lossada, C., & Cerviño, A. (2023). Exploring the Cutting Edge of Vision Science: New Developments in Diagnostics and Treatment of Ocular Surface in Dry Eye Disease. In Life (Vol. 13, Issue 7). Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/life13071584
Sánchez-González, M. C., Capote-Puente, R., García-Romera, M. C., De-Hita-Cantalejo, C., Bautista-Llamas, M. J., Silva-Viguera, C., & Sánchez-González, J. M. (2022). Dry eye disease and tear film assessment through a novel non-invasive ocular surface analyzer: The OSA protocol. Frontiers in Medicine, 9. https://doi.org/10.3389/fmed.2022.938484
Schmidl, D., Bata, A. M., Szegedi, S., Aranha Dos Santos, V., Stegmann, H., Fondi, K., Krösser, S., Werkmeister, R. M., Schmetterer, L., & Garhöfer, G. (2020). Influence of Perfluorohexyloctane Eye Drops on Tear Film Thickness in Patients with Mild to Moderate Dry Eye Disease: A Randomized Controlled Clinical Trial. Journal of Ocular Pharmacology and Therapeutics, 36(3), 154–161. https://doi.org/10.1089/jop.2019.0092
Sheppard, J. D., Evans, D. G., & Protzko, E. E. (2023). A review of the first anti-evaporative prescription treatment for dry eye disease: perfluorohexyloctane ophthalmic solution. The American journal of managed care, 29(14 Suppl), S251–S259. https://doi.org/10.37765/ajmc.2023.89464
Sheppard, J. D., Kurata, F., Epitropoulos, A. T., Krösser, S., & Vittitow, J. L. (2023). NOV03 for Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction: The Randomized Phase 3 MOJAVE Study. American Journal of Ophthalmology, 252, 265–274. https://doi.org/10.1016/j.ajo.2023.03.008
Sheppard, J. D., Torkildsen, G. L., Lonsdale, J. D., D’Ambrosio, F. A., McLaurin, E. B., Eiferman, R. A., Kennedy, K. S., & Semba, C. P. (2014). Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: Results of the OPUS-1 phase 3 study. Ophthalmology, 121(2), 475–483. https://doi.org/10.1016/j.ophtha.2013.09.015
Stapleton, F., Alves, M., Bunya, V. Y., Jalbert, I., Lekhanont, K., Malet, F., Na, K. S., Schaumberg, D., Uchino, M., Vehof, J., Viso, E., Vitale, S., & Jones, L. (2017). TFOS DEWS II Epidemiology Report. In Ocular Surface (Vol. 15, Issue 3, pp. 334–365). Elsevier Inc. https://doi.org/10.1016/j.jtos.2017.05.003
Tauber, J., Berdy, G. J., Wirta, D. L., Krösser, S., Vittitow, J. L., Alpern, L. M., Aune, C., Downing, J. E., El-Harazi, S., Evans, D. G., Goldberg, D., Greiner, J., Holland, E., Jackson, M. A., Jerkins, G. W., Kelley, K., Martel, J., Meyer, J. L., Pasquali, T., … Zimmer, D. V. (2023). NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study. Ophthalmology, 130(5), 516–524. https://doi.org/10.1016/j.ophtha.2022.12.021
Tauber, J., Wirta, D. L., Sall, K., Majmudar, P. A., Willen, D., & Krösser, S. (2021). A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease. In Cornea (Vol. 40, Issue 9). www.corneajrnl.com
Tian, L., Gao, Z., Zhu, L., Shi, X., Zhao, S., Gu, H., Xu, G., Wang, L., Dai, H., Zhang, H., Jin, X., Ma, K., Xu, Y., Ma, L., Pei, C., Ke, B., Krösser, S., Zhang, Y., & Jie, Y. (2023). Perfluorohexyloctane Eye Drops for Dry Eye Disease Associated with Meibomian Gland Dysfunction in Chinese Patients: A Randomized Clinical Trial. JAMA Ophthalmology, 141(4), 385–392. https://doi.org/10.1001/jamaophthalmol.2023.0270
Tomlinson, A., Bron, A. J., Korb, D. R., Amano, S., Paugh, J. R., Ian Pearce, E., Yee, R., Yokoi, N., Arita, R., & Dogru, M. (2011). The international workshop on meibomian gland dysfunction: Report of the diagnosis subcommittee. Investigative Ophthalmology and Visual Science, 52(4), 2006–2049. https://doi.org/10.1167/iovs.10-6997f
Wolffsohn, J. S., Arita, R., Chalmers, R., Djalilian, A., Dogru, M., Dumbleton, K., Gupta, P. K., Karpecki, P., Lazreg, S., Pult, H., Sullivan, B. D., Tomlinson, A., Tong, L., Villani, E., Yoon, K. C., Jones, L., & Craig, J. P. (2017). TFOS DEWS II Diagnostic Methodology report. In Ocular Surface (Vol. 15, Issue 3, pp. 539–574). Elsevier Inc. https://doi.org/10.1016/j.jtos.2017.05.001
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Patrycja Nowoświat, Michał Andrzej Kozicz, Paulina Cuper, Ilona Jastrzębska, Krzysztof Bilecki, Hubert Gugulski, Michał Bado, Patrycja Mrowczyk
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 160
Number of citations: 0
